Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

被引：0

作者：

Xu, Binghe ^{[1
]}

Li, Qiao ^{[1
]}

Zhang, Qingyuan ^{[2
]}

Zhang, Yue ^{[2
]}

Ouyang, Quchang ^{[3
]}

Zhang, Yang ^{[4
]}

Liu, Qiang ^{[5
]}

Sun, Tao ^{[6
]}

Xu, June ^{[7
]}

Yang, Jing ^{[7
]}

Yang, Yue ^{[7
]}

Luo, Xin ^{[7
]}

Kong, Paul ^{[7
]}

Xu, Ting ^{[7
]}

机构：

[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China

[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[3] Hunan Canc Hosp, Changsha, Peoples R China

[4] Liaocheng Peoples Hosp, Liaocheng, Shandong, Peoples R China

[5] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[6] Liaoning Canc Hosp, Dalian, Peoples R China

[7] Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1660

引用

页数：2

共 50 条

[31] Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)
Litton, J. K.
Moulder, S.
Helgason, T.
Clayborn, A. R.
Rauch, G. M.
Gilcrease, M.
Adrada, B. E.
Huo, L.
Hess, K. R.
Symmans, W. F.
Thompson, A.
Tripathy, D.
Mittendorf, E. A.
CANCER RESEARCH, 2017, 77
[32] Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer
Van Cutsem, Eric
Collignon, Joelle
Eefsen, Rikke L.
Ochsenreither, Sebastian
Zvirbule, Zanete
Ivanauskas, Audrius
Arnold, Dirk
Baltruskeviciene, Edita
Pfeiffer, Per
Yachnin, Jeffrey
Magnusson, Susanne
Millrud, Camilla Rydberg
Sanfridson, Annika
Losic, Nedjad
Garcia-Ribas, Ignacio
Tersago, Dominique
Awada, Ahmad
CLINICAL CANCER RESEARCH, 2024, 30 (23) : 5293 - 5303
[33] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
Brufsky, Adam
Kim, Sung-Bae
Zvirbule, Zanete
Dirix, Luc Yves
Eniu, Alexandru E.
Carabantes, Francisco
Izarzugaza, Yann
Mebis, Jeroen
Sohn, Joohyuk
Wongchenko, Matthew
Chohan, Saibah
Amin, Reena
McNally, V. A.
Miles, David
Loi, Sherene
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[34] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
Liu, Jieqiong
Jiang, Zefei
Li, Qian
Li, Ying
Liu, Qiang
Song, Erwei
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) plus nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC).
Schneeweiss, Andreas
Rugo, Hope S.
Winer, Eric P.
Barrios, Carlos H.
Iwata, Hiroji
Dieras, Veronique
Loi, Sherene
Maiya, Vidya
Bond, John
Lei, Guiyuan
Chui, Stephen Y.
Adams, Sylvia
Emens, Leisha A.
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] A phase Ib/II study to assess the safety and efficacy of PM8002/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer
Wu, J.
Zhang, J.
Tong, Z.
Zhang, Q.
Wang, Y.
Cheng, Q.
Chen, X.
Li, Z.
Yin, Y.
Du, Y.
Meng, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S361 - S361
[37] COLET: A multistage, phase 2 study evaluating the safety and efficacy of a doublet regimen of cobimetinib (C) in combination with paclitaxel (P) or triplet regimens of C in combination with atezolizumab (atezo) plus either P or nab-paclitaxel (nab-P) in metastatic triple-negative breast cancer (TNBC)
Miles, D.
Kim, S-B
McNally, V.
Simmons, B.
Wongchenko, M.
Xu, N.
Brufsky, A.
CANCER RESEARCH, 2017, 77
[38] Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
Cortes, Maria
Salgado, Alfonso Cortes
Murillo, Serafin Morales
Blancas, Isabel
Cortez, Patricia
Plaza, Isabel Calvo
Fernandez, Nieves Diaz
Martinez-Bueno, Alejandro
Ruiz-Borrego, Manuel
Blanch, Salvador
Llabres, Elisenda
Marme, Frederik
Schmid, Peter
Guarneri, Valentina
Gligorov, Joseph
Perez-Garcia, Jose Manuel
Sampayo-Cordero, Miguel
Malfettone, Andrea
Cussac, Antonio Llombart
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] A budget impact analysis of the VENTANA PD-L1 SP142 immunohistochemistry assay versus the Dako PD-L1 IHC 22C3 assay in patients with advanced or metastatic triple-negative breast cancer treated with atezolizumab in combination with nab-paclitaxel
Scatena, Cristian
Ravasio, Roberto
Raimondo, Paola
Giuliano, Mario
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
[40] Safety and clinical activity of cadonilimab, an anti PD-1/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer (R/M CC): A retrospective, real-world study
Fan, Shi
Wang, Tao
Zhang, Qiying
Wang, Juan
Su, Jin
Liu, Zi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →